Clinical management of cerebral small vessel disease: a call for a holistic approach

Cerebral small vessel disease (SVD) is one of the most common yet underrecognized brain disorders worldwide. It targets the tiny blood vessels in the brain—arterioles, capillaries, and venules—and slowly damages the brain’s white and gray matter. For many people, SVD progresses “silently” for years, only becoming apparent when it causes serious problems like stroke, dementia, or difficulty walking. A 2021 review by researchers from the University of Edinburgh and University of Nottingham highlights a critical gap in how we care for SVD: instead of treating individual symptoms (like a single stroke or memory loss), we need a holistic approach that addresses the whole person—their physical health, cognition, emotions, and daily life.

What Is Cerebral Small Vessel Disease?

SVD affects the brain’s “small vessels,” which supply blood to deep brain regions. Over time, these vessels can narrow, leak, or rupture, leading to:

White matter hyperintensities (WMH): Damaged white matter (the brain’s “communication cables”) visible on MRI.
Lacunes: Small strokes caused by blocked small vessels.
Microbleeds: Tiny bleeds from fragile vessels.
Enlarged perivascular spaces (PVS): Fluid-filled gaps around vessels, a sign of vessel damage.

These changes often accumulate silently. A person might have SVD for years without symptoms—until the damage reaches a “threshold” where their brain can no longer compensate.

How SVD Shows Up: From “Silent” to Life-Altering

SVD’s symptoms are often vague or attributed to aging, making it hard to diagnose early. Common signs include:

1. “Silent” SVD

Many people first learn they have SVD when an MRI is done for another reason (like a headache). While some lesions are truly asymptomatic, careful questioning often reveals subtle clues: apathy, fatigue, mild memory loss, or a change in gait.

2. Subtle Neurological Symptoms

Transient neurological attacks (TNAs)—brief, non-stroke symptoms like dizziness or numbness—are linked to SVD. These episodes can warn of future stroke or dementia.

3. Lacunar Stroke

SVD is the leading cause of lacunar strokes—small, deep brain strokes that cause symptoms like weakness, numbness, or slurred speech. Even “minor” lacunar strokes increase the risk of future disability or dementia.

4. Cognitive Decline

SVD is a top cause of vascular cognitive impairment (VCI), which includes mild memory loss (MCI) and vascular dementia. Symptoms often involve slow thinking, poor decision-making, and trouble with complex tasks (like managing finances). Unlike Alzheimer’s, VCI may progress in “steps” (after a stroke) or slowly over time.

5. Mobility and Balance Issues

SVD damages brain regions that control movement, leading to:

Slow, unsteady gait (often described as a “shuffling” walk).
Falls (a major risk for older adults).
Vascular parkinsonism: Symptoms like stiffness or bradykinesia (slow movement) that mimic Parkinson’s disease.

6. Urinary Symptoms

Studies link SVD to overactive bladder or incontinence, though more research is needed to confirm this.

Who Is at Risk for SVD?

SVD becomes more common with age—nearly everyone over 80 has some SVD changes on MRI. But it’s not just “normal aging.” Key risk factors include:

1. Hypertension (High Blood Pressure)

The most modifiable risk factor for SVD. Even mild, untreated high blood pressure damages small vessels over time. Abnormal sleep-time blood pressure (like “non-dipping” or “reverse-dipping,” where BP doesn’t drop at night) is especially risky.

2. Diabetes

Type 1 and type 2 diabetes increase the risk of lacunar strokes and cognitive decline. High blood sugar damages blood vessels and impairs brain function.

3. Lifestyle Factors

Smoking: Increases SVD burden, stroke risk, and brain shrinkage.
Diet: A high-sodium diet worsens SVD; a Mediterranean diet (rich in fruits, veggies, and healthy fats) may protect against it.
Exercise: Regular activity (even walking) helps maintain brain health, though intense exercise hasn’t been shown to reverse SVD.

4. Sleep Disorders

Obstructive sleep apnea (OSA) is associated with increased white matter hyperintensities (WMH) and silent strokes. Poor sleep quality may accelerate brain atrophy.

5. Early-Life Factors

Childhood cognitive ability, socioeconomic status (SES), and education all affect SVD risk later in life. Lower childhood IQ or education is linked to more WMH in old age—likely because these factors reduce “cognitive reserve” (the brain’s ability to compensate for damage).

How Is SVD Diagnosed?

MRI is the gold standard for diagnosing SVD. Doctors look for:

WMH (scored using the Fazekas scale, which ranges from 0–3).
Lacunes, microbleeds, and enlarged PVS.
Brain atrophy (shrinking).

CT scans can also detect SVD, though MRI is more sensitive. Imaging not only confirms SVD but also predicts progression: people with severe SVD at diagnosis are more likely to develop worse symptoms over time.

Treating SVD: What Works (and What’s Emerging)

There’s no cure for SVD, but treatments focus on slowing progression, managing symptoms, and reducing risk of stroke or dementia.

1. Lifestyle Changes

Smoking Cessation: The single best way to reduce SVD burden and stroke risk.
Diet: Cut sodium (aim for <5g/day) and eat a Mediterranean-style diet.
Exercise: Even 30 minutes of walking 5 days a week improves cognition and mobility.

2. Traditional Stroke Prevention

Antiplatelets: Aspirin or clopidogrel reduce recurrent stroke risk, but dual antiplatelets (aspirin + clopidogrel) are risky for SVD patients (higher bleeding risk).
Blood Pressure Lowering: Intensive BP control (<120/80 mmHg) slows WMH progression and reduces mild cognitive impairment (MCI) risk. Ambulatory BP monitoring (wearing a device for 24 hours) is more accurate than office BP checks.
Lipid Lowering: Statins reduce stroke risk in SVD patients with high cholesterol, though their effect on WMH is mixed.

3. Emerging Treatments

Cilostazol: A drug used in Asia for stroke prevention, cilostazol may stabilize blood vessels and slow WMH progression.
Nitric Oxide (NO) Donors: Drugs like glyceryl trinitrate (GTN) improve blood flow to the brain and may help after stroke.
Vitamins: B vitamins (B6, B12, folate) slow WMH progression in people with severe SVD.
Remote Ischemic Conditioning (RIC): A simple technique where a blood pressure cuff is inflated on the arm to “train” the body to tolerate reduced blood flow. Small studies show RIC improves cognition and reduces WMH.

The Holistic Approach: Why It’s Non-Negotiable

SVD doesn’t just affect the brain—it affects every part of a person’s life. A holistic approach means:

Multidisciplinary Care: Involve neurologists, cognitive specialists, physiotherapists, occupational therapists, and social workers to address all symptoms (cognition, mobility, mood).
Risk Factor Management: Balance medications (like BP pills) with lifestyle changes to minimize side effects.
Patient and Family Empowerment: Teach patients to monitor symptoms (e.g., using apps to track gait or cognition) and involve family in care planning (e.g., advance directives).
Long-Term Monitoring: Regular MRI scans and cognitive tests help catch progression early.

The Road Ahead: What We Need to Do

SVD research is rapidly evolving, but key gaps remain:

Better Symptom Recognition: We need to link subtle symptoms (like apathy) to SVD progression.
Personalized Treatment: Genetic and imaging studies may help identify patients who benefit most from intensive BP control or new drugs.
More Clinical Trials: We need large, long-term trials to test lifestyle interventions (like exercise) and new drugs (like cilostazol) in SVD patients.

Conclusion

Cerebral small vessel disease is a silent epidemic that touches millions of lives—but it doesn’t have to be a life sentence. A holistic approach, focused on the whole person, can slow progression, preserve independence, and improve quality of life. For patients, this means working closely with doctors, family, and caregivers to manage risk factors and monitor symptoms. For researchers, it means prioritizing trials that address SVD’s multidomain impact.

The message is clear: SVD isn’t just a “brain disease”—it’s a disease of the whole person. And caring for it requires nothing less than whole-person care.

This article is based on a 2021 review published in the Chinese Medical Journal by Una Clancy (University of Edinburgh), Jason P. Appleton (University of Nottingham/University Hospitals Birmingham), Carmen Arteaga (University of Edinburgh), Fergus N. Doubal (University of Edinburgh), Philip M. Bath (University of Nottingham/Nottingham University Hospitals), and Joanna M. Wardlaw (University of Edinburgh).

doi: https://doi.org/10.1097/CM9.0000000000001177

Was this helpful?

0 / 0